JEIL PHARMACEUTICAL CO.,LTD Logo

JEIL PHARMACEUTICAL CO.,LTD

Global manufacturer of pharmaceutical APIs, antibiotics, and injection-based treatments.

271980 | KO

Overview

Corporate Details

ISIN(s):
KR7271980005
LEI:
Country:
South Korea
Address:
서울특별시 서초구 사평대로 343 제일약품 사옥, 서초구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Founded in 1959, Jeil Pharmaceutical Co., Ltd. develops, manufactures, and distributes pharmaceutical products to promote human health. The company's core activities include the production of active pharmaceutical ingredients (APIs), intermediates, and finished medicines, with a notable focus on injection-based treatments. Operating from GMP-certified facilities, Jeil Pharmaceutical's portfolio includes various therapeutic agents, such as antibiotics. The company is expanding its reach from its domestic market to a global scale, supplying its products to other nations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-06-04 00:00
Governance Information
[기재정정]기업지배구조보고서공시
Korean 959.3 KB
2025-05-29 00:00
Governance Information
기업지배구조보고서공시
Korean 952.3 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.5 MB
2025-03-25 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 25.9 KB
2025-03-25 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 12.7 KB
2025-03-25 00:00
Board/Management Information
대표이사(대표집행임원)변경(안내공시)
Korean 5.5 KB
2025-03-17 00:00
Audit Report / Information
감사보고서제출
Korean 20.8 KB
2025-03-17 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 463.9 KB
2025-03-10 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 946.6 KB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 15.5 KB
2025-02-24 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변경
Korean 13.8 KB
2024-12-05 00:00
Share Issue/Capital Change
[기재정정]유상증자결정(종속회사의주요경영사항)
Korean 25.8 KB
2024-11-14 00:00
Quarterly Report
분기보고서 (2024.09)
Korean 1.3 MB
2024-11-08 00:00
Share Issue/Capital Change
[기재정정]유상증자결정(종속회사의주요경영사항)
Korean 23.5 KB

Automate Your Workflow. Get a real-time feed of all JEIL PHARMACEUTICAL CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for JEIL PHARMACEUTICAL CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for JEIL PHARMACEUTICAL CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NEOGENOMICS INC Logo
Provides precision oncology testing for cancer diagnostics, therapy guidance, and research.
United States of America
NEO
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America
950220
NEONC TECHNOLOGIES HOLDINGS, INC. Logo
Developing intranasal drug delivery to treat brain cancer & CNS diseases by crossing the BBB.
United States of America
NTHI
Neumora Therapeutics, Inc. Logo
Developing data-driven precision medicines for neuropsychiatric and neurodegenerative disorders.
United States of America
NMRA
Neuphoria Therapeutics Inc. Logo
Develops novel ion channel modulators for treating neuropsychiatric disorders like anxiety & PTSD.
United States of America
NEUP
NEUROCRINE BIOSCIENCES INC Logo
Develops therapies for neurological, neuroendocrine, and neuropsychiatric disorders.
United States of America
NBIX
Neurogene Inc. Logo
Developing genetic medicines using gene therapy for rare and devastating neurological diseases.
United States of America
NGNE
NeuroSense Therapeutics Ltd. Logo
Developing combination therapies for neurodegenerative diseases, with a focus on ALS.
United States of America
NRSN
NewAmsterdam Pharma Co N.V. Logo
Developing oral LDL-lowering therapies for high-risk cardiovascular disease patients.
United States of America
NAMS
Newbury Pharmaceuticals AB Logo
Develops specialty prescription drugs for Scandinavia in oncology, rare diseases & neurology.
Sweden
NEWBRY

Talk to a Data Expert

Have a question? We'll get back to you promptly.